Although the potential for drug–drug interactions in patients undergoing treatment for hepatitis C infection is decreased with the new generation of direct-acting antiviral agents (DAAs), it is by no means eliminated, according to the results of a German study.
A significant percentage of patients are at risk for such interactions if treated with modern regimens that suppress the hepatitis C virus (HCV), especially if several DAAs are used for therapy, researchers at Hannover